Coherus Oncology, Inc. Cash Flow Statement
CHRS|6 years of annual SEC 10-K data (FY2014-FY2019)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Coherus Oncology, Inc. generated $28M in operating cash flow and $27M in free cash flow in FY2019.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.49 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|
| Net Income | $89.8M | -$209.3M | -$238.2M | -$87.1M | -$53.6M | -$33.0M |
| Depreciation & Amortization | $3.3M | $3.2M | $3.4M | $674.0K | $404.0K | $221.0K |
| Operating Cash Flow | $28.4M | -$159.3M | -$200.3M | -$23.9M | $15.4M | -$18.3M |
| Capital Expenditures | $1.8M | $789.0K | $4.6M | $2.8M | $373.0K | $1.8M |
| Free Cash Flow | $26.5M | -$160.1M | -$204.9M | -$26.8M | $15.1M | -$20.0M |
| Share Buybacks | - | - | - | $2.0K | $2.0K | $2.0K |
| FCF Margin | - | - | -13165.8% | -86.1% | 547.1% | -1055.0% |